CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net product revenue	$ 27,178,000	$ 0
Cost of products sold	1,522,000	0
Gross profit	25,656,000	0
Operating expenses:
Research and development expenses	3,068,000	3,830,000
Selling, general and administrative expenses	48,623,000	24,468,000
Total operating expense	51,691,000	28,298,000
Operating loss	(26,035,000)	(28,298,000)
Investment and other income, net	1,378,000	193,000
Interest expense	(2,592,000)	(3,259,000)
Loss before income taxes	(27,249,000)	(31,364,000)
Income tax provision (benefit)	93,000	(580,000)
Net loss	$ (27,342,000)	$ (30,784,000)
Net loss per share - basic (in dollars per share)	$ (0.30)	$ (0.48)
Net loss per share - diluted (in dollars per share)	$ (0.30)	$ (0.48)
Weighted average number of shares outstanding - basic (in shares)	91,693	63,886
Weighted average number of shares outstanding - diluted (in shares)	91,693	63,886